Mounjaro
(tirzepatide)
Once-weekly injection. The only dual-action GIP and GLP-1 treatment, with the strongest results seen in clinical trials — average weight loss of 20% or more at higher doses over 72 weeks. MHRA-licensed.
LICENSED PHARMACY & UK-LICENSED DOCTORS · FREE DISCREET DELIVERY
ORFORGLIPRON · ELI LILLY · ONCE-DAILY GLP-1 TABLET
NEWFOUNDAYOTABLETS
1DAILY TABLET
~11–
72WEEKS ATTAIN-1
MHRALICENSED
Free discreet delivery
*Based on manufacturer trials. Individual results vary.
Foundayo is Eli Lilly's once-daily weight loss tablet — the first small-molecule GLP-1 pill, approved in the US in April 2026 and now licensed by the UK's MHRA. Unlike other GLP-1 tablets, it can be taken at any time of day, with or without food.
ABOUT THE MEDICATION
WHAT IS FOUNDAYO?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist from Eli Lilly — the company behind Mounjaro, which is why it's often nicknamed the 'Mounjaro pill' (a different medicine, in fact, with a different mechanism). It received FDA approval on 1 April 2026, only the second oral GLP-1 weight loss treatment approved anywhere after the Wegovy pill.
In the UK, Foundayo is licensed by the MHRA and available on private prescription after an online consultation.
How it works
01
FREE ONLINE ASSESSMENT
Complete a free online weight loss assessment.
02
PRESCRIBER REVIEW
If Foundayo is clinically appropriate for you, our GPhC-registered pharmacy will dispense your treatment.
03
FREE TRACKED DELIVERY
Free, discreet, tracked delivery — with reviews built in.
01
FREE ONLINE ASSESSMENT
Complete a free online weight loss assessment.
02
PRESCRIBER REVIEW
If Foundayo is clinically appropriate for you, our GPhC-registered pharmacy will dispense your treatment.
03
FREE TRACKED DELIVERY
Free, discreet, tracked delivery — with reviews built in.
SMALL MOLECULE VS PEPTIDE
WHY THE CHEMISTRY MATTERS
Every previous GLP-1 medicine — semaglutide, tirzepatide, liraglutide — is a peptide: a fragile protein-like molecule the digestive system destroys, which is why they're injected, and why the one oral peptide (the Wegovy pill) demands a strict fasting ritual to sneak past the stomach.
Orforglipron is different at the molecular level
A small, non-peptide molecule that survives digestion natively.
In practice
THE PRACTICAL CONSEQUENCES
No food rules
Take it any time of day, with or without food or water — the only GLP-1 with genuinely zero routine constraints.
No fridge, no needles, no sharps
A normal tablet in a normal blister.
Cheaper to make at scale
Small molecules are manufactured like conventional drugs, not brewed like biologics — a structural advantage in cost and supply resilience.
FOUNDAYO
- Small, non-peptide molecule
- MHRA-licensed in the UK
- Once-daily oral GLP-1 tablet
- No food or timing rules
Small, non-peptide molecule
MHRA-licensed in the UK
Once-daily oral GLP-1 tablet
No food or timing rules
HOW EFFECTIVE IS FOUNDAYO?
~11–12.4%
average weight loss over 72 weeks — ATTAIN-1, highest dose
- MOUNJARO (TIRZEPATIDE)~21%
- WEGOVY TABLETS~13–14%
- FOUNDAYO~11–12%
Data based on cross-trial comparisons of highest maintained doses. Individual results may vary. Clinical trials ATTAIN-1, OASIS 4, SURMOUNT-1. Not head-to-head.
The Evidence
THE ATTAIN TRIAL EVIDENCE
ATTAIN-1 — the pivotal phase 3 trial
~11–12.4%
average weight loss over 72 weeks, versus roughly 1% with placebo
In ATTAIN-1, the pivotal phase 3 trial in adults with obesity, the highest dose of orforglipron produced average weight loss of around 11–12.4% over 72 weeks, versus roughly 1% with placebo, with a meaningful proportion of participants losing 15% or more. A parallel programme (ATTAIN-2, and the ACHIEVE trials in type 2 diabetes) showed consistent effects on weight and blood sugar.
Placed honestly in the landscape
~21%
Mounjaro in SURMOUNT-1, for comparison
That's below oral semaglutide (~13–14% in OASIS 4) and well below Mounjaro (~21% in SURMOUNT-1). Foundayo's proposition isn't maximum weight loss — it's the lowest-friction GLP-1 ever made. For patients whose real-world barrier is the routine (fasting protocols, needles, cold chains), the treatment you actually take beats the stronger one you abandon.
Side effects in trials matched the GLP-1 class: predominantly nausea, constipation, vomiting and diarrhoea, dose-related and concentrated during escalation.
The alternatives
FOUNDAYO VS THE ALTERNATIVES
RELATED TREATMENTS.
Real medication. Real doctors. No inflated prices. Just results.
New — MHRA approved June 2026
Wegovy Tablets
(oral semaglutide)
New for 2026. The UK's first once-daily GLP-1 weight loss tablet, MHRA-approved in June 2026. The same active ingredient as the Wegovy injection, with comparable weight loss in trials — no needles required.
Wegovy Injection
(semaglutide)
Once-weekly injection with an average 15% weight loss over 68 weeks in the STEP 1 trial, plus proven cardiovascular benefits in people with heart disease. One of the most widely prescribed weight loss treatments worldwide. MHRA-licensed.
Brand discontinued — generic available
Liraglutide
(Saxenda)
£— / month
Once-daily injection. Branded Saxenda has been discontinued by Novo Nordisk, but generic liraglutide (Nevolat) contains the same medicine at the same dose and remains available for patients established on liraglutide or those it suits clinically.
Price includes medication only, if prescribed. An active FromMars membership is required and billed separately. Membership does not include or guarantee a prescription; medication is not available without a membership.
CHECK IF YOU QUALIFY FOR GLP-1 WEIGHT LOSS TREATMENT
GLP-1 weight loss treatments are licensed for adults who meet one of the following criteria, alongside a reduced-calorie diet and increased physical activity:
- A BMI of 30 kg/m² or above (obesity), or
- A BMI of 27 kg/m² or above (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnoea or cardiovascular disease.
BMI thresholds may be adjusted for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, who are at higher cardiometabolic risk at lower BMIs.
Meeting the BMI criteria alone doesn't guarantee suitability — our prescribers review your full medical history. GLP-1 treatments are not suitable during pregnancy or breastfeeding, or for people with a personal or family history of medullary thyroid carcinoma or MEN 2, among other contraindications your prescriber will assess.
Weight loss treatment eligibility
- 1Basic Info
- 2Ethnic group
- 3Health conditions
- 4Results
Basic Info
What is your height?
What is your weight?
Houston,
we have answers.
Houston,
we have answers.
Sources
References
- ATTAIN-1: orforglipron in adults with obesity — phase 3 results (Eli Lilly; peer-reviewed publication).
- FDA approval announcement: Foundayo (orforglipron), April 2026.
Pricing
Cost & What's Included
Foundayo is priced per monthly pack, varying by dose strength — [£X] at the starting dose to [£X] at 17.2 mg. Prices include the prescriber consultation, ongoing pharmacist support and free tracked delivery — with no cold-chain constraints, tablets also suit letterbox delivery.
- Prescriber consultation included
- Ongoing pharmacist support
- Free tracked delivery
- No cold-chain constraints — suits letterbox delivery
- No fridge, no sharps
0.8 mgStarting dose
2.5 mgStep 2
5.5 mgStep 3
9 mgStep 4
14.5 mgStep 5
17.2 mgHighest dose
READY TO START?
GET FOUNDAYO
TABLETS TODAY
Complete a free online consultation to find out if Foundayo is right for you. Prescribed by UK clinicians, dispensed by our GPhC-registered pharmacy, delivered free and discreetly.